Elanix Biotechnologies AG (DB:ELN) agreed to acquire Inno 4 Cell AG on August 22, 2017. Elanix Biotechnologies AG will fully acquire Inno 4 Cell AG within a capital increase, by way of contribution in kind using the existing authorized capital. The transaction is scheduled to be executed at the earliest after the capital increase for cash and is, amongst other things, subject to successful due diligence at Inno 4 Cell AG. As on October 17, 2017 the management board of Elanix Biotechnologies and shareholders of Inno 4 Cell agreed on further conditions for the contribution in all kinds of shares of Inno 4 Cell AG